• Hoth Therapeutics reported positive preclinical HT-VA study results on April 14, 2026, from a CRADA program with US Department of Veterans Affairs and Emory University.
• Data were already presented in this announcement, showing GDNF shifted liver fat biology toward lower fat buildup in a model of metabolic-associated fatty liver disease.
• Results indicated GDNF outperformed semaglutide on key liver-fat genetic signals, supporting a differentiated mechanism beyond weight-loss-focused approaches.
• Readout positions GDNF as a potential next-generation candidate for MAFLD and obesity, expanding Hoth’s focus beyond dermatology and oncology.
• Next steps include additional preclinical validation, evaluation of clinical development paths, and pursuit of partnerships to accelerate development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY33307) on April 14, 2026, and is solely responsible for the information contained therein.